CAMP4 Therapeutics remains in a high-risk, early-stage development phase where the proprietary regRNA platform serves as the primary value driver despite the absence of recurring commercial revenue.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.37-90.9% vs -$0.19 | — vs $2M |
Q3 2026 Aug 13, 2026 | -$0.58-174.3% vs -$0.21 | $2M+9.8% vs $2M |
Q2 2026 May 7, 2026 | -$0.32-52.4% vs -$0.21 | $1M+15.7% vs $1M |
Q2 2026 Mar 5, 2026 | -$0.87-180.6% vs -$0.31 | $300,000-36.9% vs $475,200 |
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.55 per share a year ago.
Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina Company remains on track to dose first patient by year-end 2026 Hosted Virtual Analyst Day highlighting the unmet need in SYNGAP1-related disorder and the design of the ASCEND Phase 1/2 clinical; announced SHANK3 for Phelan-McDermid syndrome as next pipeline program Received $50.1 million from second closing of private placement; cash and cash equivalents of $124.5 million as of September 30, 2026, with cash runway expected through the end of 2028 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate highlights.
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
Benchmark CAMP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CAMP4 Therapeutics Corporation (CAMP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.06 | $86.24M | -2.65 | 436.5% | -3539.93% | -261.83% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — |
CAMP4 Therapeutics Corporation (CAMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CAMP4 Therapeutics Corporation (CAMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 4, 2026·SEC
Jul 27, 2026·SEC
Get notified when CAMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAMP4 Therapeutics Corporation (CAMP) stock FAQ — growth, dividends, profitability & financials explained
CAMP4 Therapeutics Corporation (CAMP) reported $3.4M in revenue over the trailing twelve months. Revenue was $3.5M in fiscal year 2025. That is 93% less than the $49.3M of fiscal year 1996.
CAMP4 Therapeutics Corporation (CAMP) revenue fell by 10.0% over the trailing twelve months, compared with the twelve months before.
No. CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $121.1M over the trailing twelve months.
CAMP4 Therapeutics Corporation (CAMP) had a return on equity (ROE) of -261.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $26.4M over the trailing twelve months.
